Stockreport

Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
PDF Inc. ( NASDAQ:FOLD ) in a transaction valued at about $4.8 billion, a move that could strengthen BioMarin's position in rare-disease treatments. Under the terms, Amicus [Read more]